1187586-58-8

Basic information

• Product Name: Montelukast EP IMpurity E
• Synonyms: Montelukast EP IMpurity E;2-(1-((((R)-1-(3-((S)-1-(((1-(carboxymethyl)cyclopropyl)methyl)thio)-2-(7-chloroquinolin-2-yl)ethyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid;(R,S)-Montelukast Bis-sulfide;Montelukast Impurity E;1-[[[(1R)-1-[3-[(1S)-1-[[[1-(Carboxymethyl)cyclopropyl]methyl]thio]-2-(7-chloro-2-quinolinyl)ethyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio]methyl]-cyclopropaneacetic acid;Montelukast Sodium EP impurity E
• CAS NO: 1187586-58-8
• Molecular Formula: C₄₁H₄₆ClNO₅S₂
• Molecular Weight: 732.39064
• Mol File: 1187586-58-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 856.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.302±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.76±0.10(Predicted)
• CAS DataBase Reference: Montelukast EP IMpurity E(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast EP IMpurity E(1187586-58-8)
• EPA Substance Registry System: Montelukast EP IMpurity E(1187586-58-8)

Safety Data

• Hazardous Substances Data: 1187586-58-8(Hazardous Substances Data)

Usage

Uses

(R,S)-Montelukast Bis-sulfide (Montelukast EP Impurity E; Montelukast USP Related Compound D) is an impurity of Montelukast and is a part of the diastereomer mixture Montelukast Bis-Sulfide (M567985).

Upstream product

• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 1197414-05-3 C₂₉H₂₆ClNO 
• 869066-93-3 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl acetate 
• 1197374-10-9 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propan-1-ol hydrochloride 
• 152922-73-1 2-[1-(mercaptomethyl)cyclopropyl]acetic acid methyl ester 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 1197374-12-1 [1-[(R)-1-(3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]-phenyl)-3-(2-isopropenylphenyl)propylsulfanylmethyl]cyclopropyl]acetic acid dicyclohexylamine salt 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1197374-11-0 (S)-1-(3-((E)-2-(7-chloroquinolin?2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl methanesulphonate 
• 1351973-24-4 C₄₁H₄₄ClNO₄S₂ 
• 918972-54-0 [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-[1-(1-methyl)ethenyl]phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 

Relevant articles and documents

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.